Celladon (CLDN) Stock Sinks On Failed Trial

Shares of Celladon Corporation (CLDN) tumbled 75% in premarket trading Monday morning, putting them on track to extend their 2015 slump of 30 percent. The nosedive being attributed to negative results for CUPID2 Trial of MYDICAR(R) in Advanced Heart Failure. Celladon said its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. […] View the full post at: Celladon (CLDN) Stock Sinks On Failed Trial Related posts: Casino capitalism on trial Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock ARCA Biopharma Shares More than Double on Heart Drug Patent